Table 1. Risk Stratification of Primary GIST by Mitotic Index, Tumor Size, and Tumor Locationa
| Mitotic Index, hpf | Size, cm | Site and Risk of Progressive Disease (%) | |||
| Gastric | Duodenum | Jejunum/Ileum | Rectum | ||
| ≤5 per 50 | ≤2 | None (0) | None (0) | None (0) | None (0) |
| >2 ≤5 | Very low (1.9) | Low (4.3) | Low (8.3) | Low (8.5) | |
| >5 ≤10 | Low (3.6) | Moderate (24) | (Insufficient data) | (Insufficient data) | |
| >10 | Moderate (10) | High (52) | High (34) | High (57) | |
| >5 per 50 | ≤2 | None | Highb | (Insufficient data) | High (54) |
| >2 ≤5 | Moderate (16) | High (73) | High (50) | High (52) | |
| >5 ≤10 | High (55) | High (85) | (Insufficient data) | (Insufficient data) | |
| >10 | High (86) | High (90) | High (86) | High (7) | |
| GIST = gastrointestinal stromal tumors; hpf = high-power field, assessed from an area that on initial screen appears to have the highest mitotic activity. | |||
| aAnnual review of pathology by ANNUAL REVIEWS, INC. Reproduced with permission of ANNUAL REVIEWS, INC., in the format Internet posting via Copyright Clearance Center.[2] | |||
| bSmall numbers of cases. |
References
- Corless CL, Heinrich MC: Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol 3: 557-86, 2008. [PUBMED Abstract]
